Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer

Author： O'Sullivan Ciara C   Swain Sandra M  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.13, Iss.5, 2013-05, pp. : 779-790

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MicroRNA and HER2-overexpressing Cancer

By  

MicroRNA, Vol. 2, Iss. 2, 2013-08 ,pp. : 137-147

Bentham Science Publishers

Access to resources Recommend Favorite

HER2 as a target for breast cancer therapy

By Tagliabue Elda   Balsari Andrea   Campiglio Manuela   Pupa Serenella M  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 5, 2010-05 ,pp. : 711-724

Informa Healthcare

Access to resources Recommend Favorite

Pertuzumab for the treatment of ovarian cancer

By Langdon Simon P   Faratian Dana   Nagumo Yoko   Mullen Peter   Harrison David J  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 7, 2010-07 ,pp. : 1113-1120

Informa Healthcare

Access to resources Recommend Favorite

HER-dimerization inhibitors: evaluating pertuzumab in women's cancers

By Kristjansdottir Katrin   Dizon Don  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 2, 2010-02 ,pp. : 243-250

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor

By Simonds Hannah M   Miles David  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 4, 2007-04 ,pp. : 487-491

Informa Healthcare

Access to resources Recommend Favorite